Moderna MRNA shares suffered a sharp reversal on Friday, falling close to 10% after a strong October rally had pushed the biotechnology to its 52-week high.
The shares, which reached $242.29 during their recent advance, were trading near $213 at the time of writing. The decline erased a significant portion of this month’s gains, which had exceeded 25% before Friday’s session.
Despite the latest retreat, Moderna has been one of the market’s strongest performers over the past 12 months, with its stock rising close to 700%. Progress in the company’s cancer treatment research has helped fuel investor enthusiasm, but the rapid appreciation has also put its valuation under greater scrutiny.
Analyst targets lag behind the share price
The sell-off mimicked a negative trading day for the broader market. Moderna’s peers recorded more modest moves, with Pfizer gaining 0.42% while BioNTech fell around 2.5%.
The sharp difference in performance suggests that Moderna faced company-specific selling pressure rather than simply following the wider biotechnology sector lower. Profit booking can be explained as one of the reasons but there were other catalysts as well.
One factor drawing attention was Goldman Sachs’ latest assessment of the stock. The investment bank increased its price target to $137 from $120 but kept its Neutral rating unchanged.
With Moderna trading around $212, Goldman’s revised valuation remains considerably below the prevailing share price. The change therefore offered limited support for investors looking for further confirmation that the recent rally could continue.
The cautious stance follows Citigroup’s decision to downgrade Moderna to Sell recently. Together, the analyst views highlight a growing divide between the market’s enthusiasm for the company’s progress and the valuations.
Cancer treatment remains central to the investment story
Much of the interest in Moderna has centred on its efforts to expand beyond vaccines into cancer treatment. The stock had dipped sharply post COVID-19 but has witnessed a dramatic turnaround since last year.
In August, the company reported positive Phase 3 results for its personalized cancer vaccine, strengthening expectations that the treatment could become an important part of its future business.
The therapy, intismeran autogene, is being developed in partnership with Merck. Investors are now awaiting more detailed findings from the late-stage trial to assess the treatment’s potential more closely.
The upcoming data could help clarify whether the clinical progress that has helped drive Moderna’s stock higher can translate into a commercially significant treatment.
For investors, however, the timing creates a difficult balance. Expectations surrounding the cancer vaccine have contributed to the stock’s substantial gains, leaving the market to judge how much potential success is already reflected in the share price.
Can the rally regain momentum?
Friday’s decline illustrates the pressure that can emerge when a stock advances rapidly ahead of further evidence to support its valuation.
Moderna’s progress in cancer treatment has reshaped investor expectations, but analysts’ price targets suggest that confidence in the science does not necessarily translate into agreement about the stock’s current worth.
The next detailed results for intismeran autogene will be an important point of focus as investors evaluate the treatment’s prospects and Moderna’s longer-term growth potential.
The post Why is Moderna down 10% on Friday? appeared first on Invezz
